Immediate vs. Deferred Switching from a Boosted Protease Inhibitor (PI/r) Based Regimen to a Dolutegravir (DTG) Based Regimen in Virologically Suppressed Patients with High Cardiovascular Risk or Age ≥50 years: Final 96 Weeks Results of NEAT 022 study

Immediate vs. Deferred Switching from a Boosted Protease Inhibitor (PI/r) Based Regimen to a Dolutegravir (DTG) Based Regimen in Virologically Suppressed Patients with High Cardiovascular Risk or Age ≥50 years: Final 96 Weeks Results of NEAT 022 study / Gatell, José M; Assoumou, Lambert; Moyle, Graeme; Waters, Laura; Johnson, Margaret; Domingo, Pere; Fox, Julie; Martinez, Esteban; Stellbrink, Hans-Jürgen; Guaraldi, Giovanni; Masia, Mar; Gompels, Mark; De Wit, Stephane; Florence, Eric; Esser, Stefan; Raffi, François; Stephan, Christoph; Rockstroh, Juergen; Giacomelli, Andrea; Vera, Jaime; Bernardino, José Ignacio; Winston, Alan; Saumoy, Maria; Gras, Julien; Katlama, Christine; Pozniak, Anton L. - In: CLINICAL INFECTIOUS DISEASES. - ISSN 1058-4838. - 68:4(2019), pp. 597-606. [10.1093/cid/ciy505]